The experience of the founding team of CanFel Therapeutics spans the drug discovery process from the initial research proof of concept, to regulatory filings, to the final drug manufacturing and clinical campaign. The team has proven experience in the successful start-up and growth of a cancer therapeutics company.

Our mission:
Create a commercially viable pipeline of therapeutics for companion animals, the result of an innovative and progressive research and development platform

Jennie P. Mather, Ph.D.

Dr. Mather has unusually broad experience that spans basic research in cancer biology as an Assistant Professor at The Rockefeller University to applied research in product discovery and development at Genentech, and Raven biotechnologies, a company she founded in 1999. During 15 years at Genentech, Dr. Mather led or participated in 12 project teams that produced eight of Genentech's marketed products, including the monoclonal antibodies Herceptin® and Avastin ® for treatment of cancer.

Dr. Mather is an inventor on 40 issued patents. These include serum-free media for manufacturing proteins; methods of isolation of normal tissue stem cell lines and cancer stem cell lines; monoclonal antibodies and targets for cancer drugs, and use patents on multiple products. Dr. Mather is the distinguished recipient of numerous industry and government awards including recognition by the USPTO, PCT (WIPO), HBA, Red Herring Magazine and World Economic Forum.

John B. Whelan, MBA

John B. Whelan has extensive experience growing, managing and financing biotech companies. He is a founder of CanFel Therapeutics and currently serves as a Director. Prior to his positions as CEO and Chief Financial Officer at AP Pharma, he was Chief Operating Officer and Chief Financial Officer at Raven biotechnologies (acquired by MacroGenics), where he oversaw the finance function as well as having broad operational responsibilities. Mr. Whelan also held the position of Vice President and Chief Financial Officer at Eos Biotechnology (acquired by PDL), where he was responsible for finance, business development, and administration.

Earlier, Mr. Whelan held a number of management positions at Hewlett Packard/Agilent, culminating in his tenure as Director of Corporate Development, during which he led the consummation of numerous acquisitions, investments, and collaborations with companies in the life sciences, medical devices, and computing industries. Mr. Whelan has a BS in Engineering from the University of California, Berkeley and an MBA from the Anderson Graduate School of Management at UCLA.

Penelope Roberts

Penelope Roberts, co-founder and Senior Scientist at Raven biotechnologies, was instrumental in establishing the technology, systems integration and workflow for the antibody pipeline at Raven. A key contribution was the establishment of numerous normal-tissue and cancer-tissue stem cell lines. Prior to the work at Raven, she spent 13 years at Genentech, Inc., in the departments of Research and Cell Culture Process Development. She has co-authored a textbook on cell culture, is an author of more than 20 peer-reviewed publications and an inventor on 15 issued patents.

Tony Liang

Tony W. Liang has had broad academic and industry research experience spanning over 20 years. These research areas have covered developmental biology, epithelial biology, immunology, antibody characterization, protein purification and assay development. Mr. Liang has previously worked at Genentech, Inc, Raven biotechnologies, inc., Macrogenics, Inc., and CytomX. Mr. Liang is an author on 16 peer-reviewed journal articles and an inventor on four issued US patents.